Fierce Pharma

AUGUST 30, 2023

After settling a patent case with Vivitrol maker Alkermes, Teva has gained a license to launch its generic version of the opioid dependence and alcohol dependence med years ahead of the drug's pate | Under the patent settlement, Teva will be able to launch its generic two years ahead of the 2029 patent expiration for Vivitrol.

189

189

PharmaTimes

MAY 28, 2024

The MRC BRC and the MDU will use the funding and cutting-edge research to improve public health until March 2029

Medical 115

Medical 115

Pharmaceutical Technology

FEBRUARY 8, 2024

In recognition of its 30th anniversary, the International Gaucher Alliance (IGA) unveiled a visionary five-year strategic plan extending to 2029.

52

52

pharmaphorum

NOVEMBER 21, 2024

Novartis has raised its guidance for sales growth out to 2029 on the strength of its pipeline and the potential of late-stage R&D assets

Sales 98

Sales 98

European Pharmaceutical Review

FEBRUARY 20, 2024

million by 2029. percent between 2022 and 2029. A report from Data Bridge Market Research has predicted that the upstream bioprocessing market will value $14,256.78 Additionally, the research calculated that market is anticipated to undergo a CAGR of 6.85

Marketing 98

Marketing Manufacturing Media Pharmaceutical 98

European Pharmaceutical Review

JANUARY 21, 2025

billion in 2029 at a compound annual growth rate (CAGR) of 7.9 Their report ascertained that growth between 2019-2024 resulted from factors such as quality control demands, cost efficiency, rapid analysis, market competition, healthcare innovations. The market is expected to see strong growth in the next few years, the authors asserted.

Marketing 59

Marketing Competition Pharmaceutical Healthcare 59

World of DTC Marketing

AUGUST 7, 2022

would permit Medicare to negotiate the prices of 10 drugs, scaling up to 20 by 2029. Currently, the government is forbidden to negotiate drug prices; the Inflation Reduction Act proposed by Senate Majority Leader Charles E. Schumer (D-N.Y.) Joe Manchin III (D-W.Va.)

Insurance 263

Insurance Doctors Government Physicians 263

Pharmaceutical Technology

JUNE 12, 2023

In 2022, the FDA awarded VX-548 breakthrough therapy and fast-track designations for post-operative pain, and the drug is forecast to reach sales of $416m by 2029. A promising example includes Vertex Pharmaceuticals’s VX-548, a sodium channel subunit blocker.

Medical 143

Medical Prescription Management Manufacturing 143

Pharmaceutical Technology

JULY 31, 2023

According to GlobalData, it is projected that the market for hepatitis B treatments will experience a sharp increase over the next six years.

Marketing 52

Marketing 52

MaBiCo

JANUARY 21, 2025

According to some researchers and AI experts, there is a possibility that for people who are careful with their health and use new treatments, the rate of increase in life expectancy will reach 12 months per year, reaching the so-called “longevity escape velocity” between 2029 and 2035.

Medical science 96

Medical science Medicine Patients Management 96

Pharmaceutical Technology

SEPTEMBER 22, 2023

According to GlobalData, the number of individuals affected by rheumatoid arthritis is anticipated to rise to 6,980,823 cases by 2029.

59

59

European Pharmaceutical Review

JUNE 26, 2024

Completion is expected between 2027 and 2029. This is compared to the company’s $3.9 (DKK DKK 26 billion) investment in 2023, not including acquisitions. Initial construction work has begun on the new facility. Haemophilia drug could reduce treated bleeding episodes … The post New US fill finish facility receives $4.1

Manufacturing 104

Manufacturing Pharmaceutical 104

Pharmaceutical Technology

JUNE 24, 2024

The KRAS inhibitor, Krazati, is expected to generate $1.3bn in global sales in 2029, as per GlobalData’s analysis.

FDA 52

FDA Sales 52

European Pharmaceutical Review

MAY 20, 2024

It is anticipated that operations will be ready to commence from 2029. The pharmaceutical firm stated that it is planning to begin the design and construction of the manufacturing facility by the end of 2024.

Manufacturing 98

Manufacturing Biopharma Pharmaceutical Pharma 98

Pharmaceutical Technology

JUNE 27, 2024

Ohtuvaye is expected to rake in $1.1bn in global sales from the market for COPD patients with moderate to severe exacerbations by 2029.

FDA 52

FDA Sales Marketing Patients 52

European Pharmaceutical Review

NOVEMBER 10, 2023

The construction projects will be finalised from the end of 2025 through to 2029. Once equipped, the facility is expected to create a total of 800 jobs: 700 jobs in the new API facility and 100 jobs in the new packaging facility.

Manufacturing 111

Manufacturing Pharmaceutical manufacturing Pharmaceutical Medicine 111

European Pharmaceutical Review

APRIL 19, 2024

Ensuring competitiveness in Europe European Federation of Pharmaceutical Industries and Associations (EFPIA) response EFPIA Director General, Nathalie Moll asserted that conditions must be created to drive R&D in Europe, “supporting investment in high-tech, sustainable manufacturing while maintaining open, global supply chains”.

Competition 105

Competition Pharmaceutical Manufacturing Specialization 105

European Pharmaceutical Review

FEBRUARY 21, 2024

Research predicts 2029 small molecule oncology market leaders The post EGFR inhibitor could provide major advance in lung cancer appeared first on European Pharmaceutical Review. Results from a Phase III trial in the neoadjuvant setting are expected later in 2024.

Distribution 105

Distribution Patients Medical Pharmaceutical 105

PharmaTech

AUGUST 21, 2024

This Behind the Headlines news roundup panel discussion covers news items such as the resurgence of mpox in Africa, “medical tourism” in India, Eli Lilly’s new Boston CGT facilities, and contract development and manufacturing organization (CDMO) projected growth rates for the 2023–2029 period, and the reasons behind them.

Manufacturing 52

Manufacturing FDA Medical 52

Pharmaceutical Technology

NOVEMBER 1, 2023

The Amgen biosimilar Wezlana has been approved for all indications and is forecasted to yield $455m in 2029.

FDA 52

FDA 52

European Pharmaceutical Review

JANUARY 3, 2024

As a result, this approach could treat diseases addressing previously inaccessible drug targets, the company stated. $2

CRM 98

CRM Pharmaceutical Pharma Management 98

Pharmaceutical Commerce

JANUARY 5, 2024

US biosimilars market projected to grow from less than $10 billion in 2022 to more than $100 billion by 2029.

Marketing 52

Marketing 52

Pharmaceutical Technology

OCTOBER 23, 2023

The Remicade biosimilar is forecasted to have sales of $2.3bn by 2029 as a subcutaneous form is approved for the US market.

FDA 52

FDA Sales Marketing 52

Pharmaceutical Technology

AUGUST 31, 2023

Daiichi Sankyo and AstraZeneca’s blockbuster anti-cancer drug Enhertu could become a pan-tumour drug, with projected sales of $9.9bn by 2029.

FDA 52

FDA Sales 52

Pharmaceutical Technology

SEPTEMBER 23, 2022

It is expected to expire on 21 January 2029, with paediatric exclusivity lasting until 21 July 2029. It will expire on 24 November 2026, and the paediatric exclusivity lasts until 24 May 2027. Merck’s second patent covers the co-formulation of sitagliptin and metformin present in Janumet.

Food and Drug Administration 69

Food and Drug Administration FDA Food Marketing 69

Pharmaceutical Technology

MAY 10, 2023

billion in global sales in 2029, while Truvada estimates amount to $30 million. Truvada has since gone generic, with Teva Pharmaceuticals launching the first FDA-approved Truvada generic in October 2020. According to a consensus forecast from GlobalData’s Pharma Intelligence Centre, Descovy is estimated to yield $1.83

Government 105

Government FDA Pharmaceutical Sales 105

pharmaphorum

NOVEMBER 18, 2022

Its CW-2029 – developed in collaboration with AbbVie – is an investigational, conditionally activated ADC directed towards CD71 and has demonstrated encouraging anti-tumour activity in patients with squamous non-small cell lung cancer (NSCLC).

Biopharma 105

Biopharma Physicians Sales Patients 105

European Pharmaceutical Review

JUNE 12, 2023

The facility is expected to start producing API by early 2029. Novo Nordisk explained that, according to internal calculations, production in the future facility in Hillerød will reduce water consumption by more than 40 percent and energy consumption by more than one third, compared to similar API processes in other facilities.

Manufacturing 98

Manufacturing Government Pharmaceutical Medicine 98

European Pharmaceutical Review

JUNE 28, 2023

If commercialisation is successful, obicetrapib is expected to value $619 million in sales by 2029, stated GlobalData. According to GlobalData, the CETP inhibitor obicetrapib is in the pipeline for dyslipidaemia. The treatment is expected to launch in 2028 in the US, EU, and Japan. appeared first on European Pharmaceutical Review.

Patients 97

Patients Sales Medical Pharmaceutical 97

Clarivate

JANUARY 8, 2024

Clarivate data indicates a 90% probability that datopotamab deruxtecan will win marketing authorization in the United States, and projects 2029 sales of $2.7 billion in 2029 for CASGEVY alone. FDA accelerated approval in August, Clarivate projects the drug will see $850 million in sales by 2029. billion in 2029 revenues.

Marketing 59

Marketing Patients Healthcare Healthcare 59

European Pharmaceutical Review

FEBRUARY 5, 2024

Research predicts 2029 small molecule oncology market leaders A “big step forward” for biotech innovation In a similar move, legislation to restore immediate R&D expensing was passed in the US House of Representatives on 31 January 2024.

Food and Drug Administration 97

Food and Drug Administration Medicine Food Pharmaceutical 97

pharmaphorum

OCTOBER 26, 2022

Ofev is, however, heading for patent expiry in 2029, and Boehringer is looking to BI 1015550 to maintain the franchise beyond that date, and also to improve the treatment of IPF, which remains incurable. First approved back in 2014, it is still growing strongly, with its 2021 sales of €2.5

Recruitment 98

Recruitment Prospecting Marketing Patients 98

Pharmaceutical Technology

MAY 12, 2023

GlobalData analyst consensus forecasts project sales to reach $11.5bn by 2029, a 29% compound annual growth rate (CAGR). GlobalData analysts predict the total revenue to be generated from currently marketed Seagen ADCs to be roughly $30bn through 2029. targeting ADC.

Sales 64

Sales Marketing 64

Pharmaceutical Technology

APRIL 28, 2023

In 2022, US sales of Ozempic contributed to 65% of global sales; this is expected to continue, with the US market forecast to continue capturing the majority of sales, generating $71bn between 2023–2029. It is forecast that Ozempic will sustain its sales growth over the next five years, with an expected annual sales figure of $17bn in 2029.

Sales 52

Sales Marketing Medical Patients 52

Pharmaceutical Technology

MAY 19, 2023

GlobalData forecasts Rituxan sales to plummet to just over $300m by 2029, while biosimilars will collectively surpass $1bn in sales in the same year, becoming responsible for nearly 80% of the total market share for rituximab products. However, in the second year of biosimilar competition, Rituxan sales started to significantly erode.

Sales 59

Sales Competition Marketing Patients 59

Pharmaceutical Technology

JULY 20, 2023

By 2029, RSV drugs are forecast to surpass $9bn in sales, This surge can be attributed to recent developments in preventative measures.

Marketing 40

Marketing Sales 40

European Pharmaceutical Review

JANUARY 2, 2024

According to the research, the global cell and gene therapy market is predicted to value $80 billion by 2029. The field of oncology is anticipated to hold 44 percent of the market by this year.

Manufacturing 98

Manufacturing Marketing Engineering Pharma 98